D. Mathez

发表

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

J Leibowitch, G. Carcelain, R. Tubiana, 1997, Science.

Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy.

J. Alvarez, P. de Truchis, A. Dinh, 2010, AIDS.

Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro

R. Schinazi, D. Liotta, D. Mathez, 1993, Antimicrobial Agents and Chemotherapy.

NEEDLESTICK HIV SEROCONVERSION IN A NURSE

N. Monplaisir, D. Mathez, J. Leibowitch, 1986, The Lancet.

Oxygen consumption by cultured human cells is impaired by a nucleoside analogue cocktail that inhibits mitochondrial DNA synthesis.

R. Naviaux, A. Lesne, T. Leste-Lasserre, 2005, Mitochondrion (Amsterdam. Print).

T cell changes after combined nucleoside analogue therapy in HIV primary infection.

G. Carcelain, B. Autran, P. Debré, 1999, AIDS.

Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo

F. Mammano, S. Paulous, F. Clavel, 1998, Journal of Virology.

HTLV AND AIDS IN FRANCE

M. Essex, D. Zaguri, D. Mathez, 1984, The Lancet.

Short cycles of antiretroviral drugs provide intermittent yet effective therapy: a pilot study in 48 patients with chronic HIV infection

J. Melchior, C. Perronne, D. Mathez, 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection

T. Calvez, R. Lancar, D. Mathez, 2003, AIDS.

Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo

M. Clementi, L. Butini, S. Aquaro, 1996, Journal of virology.

Acute Urinary Retention Due to Viral Coinfections (HIV, HBV, VZV)

P. Denys, J. Salomon, M. Durand, 2010, Journal of the International Association of Physicians in AIDS Care.

Infectious Amplification ofWild-Type Human Immunodeficiency VirusfromPatients' Lymphocytes and Modulation byReverse Transcriptase Inhibitors InVitro

D. Mathez, J. Leibowitch, 1993 .

Lymphadenopathy-associated virus/human T-lymphotropic virus type III in allogeneic bone marrow transplantation.

P. Bierling, C. Cordonnier, D. Mathez, 1986, Annals of internal medicine.

Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial

C. Katlama, M. Duracinsky, D. Costagliola, 2018, The Journal of antimicrobial chemotherapy.

Productive human immunodeficiency virus infection levels correlate with AIDS-related manifestations in the patient.

W. Saurin, I. Gorin, Y. Sultan, 1990, Proceedings of the National Academy of Sciences of the United States of America.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

ANTIBODIES TO HTLV-III ASSOCIATED ANTIGENS IN POPULATIONS EXPOSED TO AIDS VIRUS IN FRANCE

S. Matheron, D. Zaguri, D. Mathez, 1984, The Lancet.

Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients

C. Delaugerre, J. Molina, S. Gallien, 2012, PloS one.

LAV/HTLV-III seroconversion and disease in hemophiliacs treated in France.

Y. Sultan, D. Mathez, P. Maisonneuve, 1986, The New England journal of medicine.

The adult penile urethra is a novel entry site for HIV-1 that preferentially targets resident urethral macrophages

M. Vacher-Lavenu, M. Bomsel, A. Schmitt, 2012, Mucosal Immunology.

Maraviroc Intensification in HIV-1 Infected Patients with Persistant Low-levelViremia

E. Rouveix, C. Dupont, D. Mathez, 2016 .

Restoration of the immune system with anti-retroviral therapy.

V. Calvez, C. Katlama, B. Autran, 1999, Immunology letters.

Four days a week or less on appropriate anti‐HIV drug combinations provided long‐term optimal maintenance in 94 patients: the ICCARRE project

G. Carcelain, J. Izopet, J. Melchior, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Quantitation of Blood Lymphocyte Mitochondrial DNA for the Monitoring of Antiretroviral Drug‐Induced Mitochondrial DNA Depletion

R. Naviaux, T. Leste-Lasserre, C. Petit, 2003, Journal of acquired immune deficiency syndromes.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.

M. Sinet, C. Gaudebout, F. Chau, 2000, AIDS research and human retroviruses.

Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients

C. Delaugerre, G. Peytavin, P. de Truchis, 2007, AIDS.

Meningoencephalitis Due to HIV Replication Despite Plasmatic Viral Control

R. Carlier, J. Salomon, L. Bernard, 2011, Journal of the International Association of Physicians in AIDS Care.

Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.

C. Katlama, R. Mills, M. Clementi, 1997, Antiviral Therapy.

Letter to the Editor: Long-Term Control of Viral Residual Replication Under Maintenance Therapy with Trizivir After a Quadruple Induction Regimen in HIV-1-Infected Adults (Suburbs Trial)

E. Rouveix, D. Mathez, J. Leibowitch, 2007, HIV clinical trials.